India needs to increase the pace of research in regenerative medicine to come up to the global level, especially in the area of clinical trials and regulatory requirements, a doctor said on Saturday.
“Autologous cell therapies with minimum manipulation also need standardisation. A national level consortium should be formed consisting of governing authorities, academia, industry
He was speaking at the International Conference on Regenerative Medicine and Stem Cells.
Mahajan was invited to share his knowledge on Mesenchymal Stem Cells- the new drug on the horizon. During the conference he emphasised on how a single cell when applied properly can work as a multi-action drug.
According to Mahajan, one of the reasons India
“With advent of cell based therapy and their availability such disease conditions can reduce these burdens to a great extent,” said Mahajan.